檢索結果 - Francesco Passamonti

Refine Results
  1. 1
    How I treat polycythemia vera

    How I treat polycythemia vera 由 Francesco Passamonti

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Clinical relevance of JAK2 (V617F) mutant allele burden

    Clinical relevance of JAK2 (V617F) mutant allele burden 由 Francesco Passamonti, Elisa Rumi

    出版 2009
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  3. 3
    Update from the latest WHO classification of MPNs: a user’s manual

    Update from the latest WHO classification of MPNs: a user’s manual 由 Francesco Passamonti, Margherita Maffioli

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    The role of JAK2 inhibitors in MPNs 7 years after approval

    The role of JAK2 inhibitors in MPNs 7 years after approval 由 Francesco Passamonti, Margherita Maffioli

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Myelofibrosis

    Myelofibrosis 由 Francesco Passamonti, Barbara Mora

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

    Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia 由 Alessandro Squizzato, Erica Romualdi, Francesco Passamonti, Saskia Middeldorp

    出版 2013
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  7. 7
    Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies

    Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies 由 Francesco Passamonti, Margherita Maffioli, Domenica Caramazza, Mario Cazzola

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis

    Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis 由 Francesco Passamonti, Francisco Cervantes, Alessandro M. Vannucchi, Enrica Morra, Elisa Rumi, Mario Cazzola, Ayalew Tefferi

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Anemia in myelofibrosis: Current and emerging treatment options

    Anemia in myelofibrosis: Current and emerging treatment options 由 Francesco Passamonti, Claire Harrison, Ruben A. Mesa, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Srđan Verstovšek

    出版 2022
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  10. 10
    Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype

    Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is... 由 Ayalew Tefferi, Sergio Siragusa, Kebede Hussein, Susan M. Schwager, Curtis A. Hanson, Animesh Pardanani, Francisco Cervantes, Francesco Passamonti

    出版 2009
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis 由 Nico Gagelmann, Francesco Passamonti, Christine Wolschke, Radwan Massoud, Christian Niederwieser, Raissa Adjallé, Barbara Mora, Francis Ayuk, Nicolaus Kröger

    出版 2021
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  12. 12
    A Gain-of-Function Mutation of<i>JAK2</i>in Myeloproliferative Disorders

    A Gain-of-Function Mutation of<i>JAK2</i>in Myeloproliferative Disorders 由 Róbert Královics, Francesco Passamonti, Andreas Buser, Soon-Siong Teo, Ralph Tiedt, Jakob Passweg, André Tichelli, Mario Cazzola, Radek C. Skoda

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

    Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS 由 Chiara Elena, Francesco Passamonti, Elisa Rumi, Luca Malcovati, Luca Arcaini, Emanuela Boveri, Michele Merli, Daniela Pietra, Cristiana Pascutto, Mario Lazzarino

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

    Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients 由 Elisa Rumi, Francesco Passamonti, Chiara Elena, Daniela Pietra, Luca Arcaini, C. Astori, Silvia Zibellini, Emanuela Boveri, C. Pascutto, Mario Lazzarino

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up

    Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuv... 由 Ercole Brusamolino, A. Baio, Ester Orlandi, Luca Arcaini, Francesco Passamonti, Vassiliki Griva, William Casagrande, Cristiana Pascutto, P. Franchini, Mario Lazzarino

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia

    Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia 由 Guido Finazzi, Alessandra Carobbio, Paola Guglielmelli, Chiara Cavalloni, Silvia Salmoiraghi, Alessandro M. Vannucchi, Mario Cazzola, Francesco Passamonti, Alessandro Rambaldi, Tiziano Barbui

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib

    Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib 由 Francesco Passamonti, Siddhi Korgaonkar, Rohan Parikh, Manoj Chevli, Aylin Yücel, Julien Rombi, Shalon Jones, Dieter Zissler, Keith L. Davis, Samantha Slaff

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

    The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms 由 Damla Olcaydu, Elisa Rumi, Ashot S. Harutyunyan, Francesco Passamonti, Daniela Pietra, Cristiana Pascutto, Tobias Berg, Roland Jäger, E. Hammond, M. Cazzola, Róbert Královics

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

    Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 由 Róbert Královics, Soon-Siong Teo, Andreas Buser, Martin Brutsche, Ralph Tiedt, André Tichelli, Francesco Passamonti, Daniela Pietra, Mario Cazzola, Radek C. Skoda

    出版 2005
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Defining disease modification in myelofibrosis in the era of targeted therapy

    Defining disease modification in myelofibrosis in the era of targeted therapy 由 Naveen Pemmaraju, Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, Jacqueline S. Garcia, Joseph M. Scandura, Stephen T. Oh, Francesco Passamonti, Konstanze Döhner, Adam J. Mead

    出版 2022
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:

檢索工具: